EW Edwards Lifesciences Corporation Common Stock
$91,21
Prezzo · Ago 18, 2026
Fondamentali al Ago 4, 2026
Intervallo 52 sett.
$72–$96
79% of range
Rating Analisti
BUY
40 analysts
Prezzo Obiettivo
$101
+11% upside
P/E (TTM)
56.6
ROE
10.6%
Margine di Profitto Netto
17.7%
Informazioni su Edwards Lifesciences Corporation Common Stock Panoramica della società da Wikipedia
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
Leggi di più
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027.
History
Edwards Lifesciences was originally founded by electrical engineer Miles "Lowell" Edwards in 1958, a graduate of Oregon State University. Edwards invented the first medically proven and adopted artificial heart valve. Dr. Albert Starr, a surgeon at the Oregon Health and Sciences University, is credited as the first to successfully implant the Starr-Edwards mitral valve in a patient in 1960. As a result of the successful heart implant, Edwards established manufacturing in Santa Ana, California the same year to continue his research in pulmonary devices.
Edwards' valves are still in operation today. An early patient lived a record 48 years with the implant before requiring a replacement.
Edwards was acquired by Baxter in 1985. It was spun off from Baxter in 2000.
In 2017, Edwards completed the acquisition of Valtech Cardio for $340 million. Also in 2017, Edwards acquired Harpoon Medical of Baltimore, Maryland for $100 million. Harpoon, founded in 2013, developed a minimally invasive heart surgery product for mitral valve repair to treat degenerative mitral regurgitation. At the time of the acquisition, the product was not available on any market.
On April 18, 2019, Edwards completed the acquisition of CAS Medical Systems of Branford, Connecticut for ~$100 million.
Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valve systems were FDA-approved for the treatment of patients at low risk for death or major complications associated with open-heart surgery on August 16, 2019. These products are used to treat patients with severe aortic stenosis without utilizing open-heart surgery.
In 2020, Edwards co-sponsored the Virtual ISPOR-FDA Summit centered on patient preference information in medical device regulatory decisions.
In December 2021, the FDA approved the SAPIEN 3 transcatheter valve in combination with the Alterra adaptive prestent for the treatment of severe pulmonary regurgitation.
In February 2024, the FDA approved Edwards' EVOQUE tricuspid valve replacement system, the first transcatheter therapy approved in the United States for the treatment of tricuspid regurgitation. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
In June 2024, the company received FDA approval for a new implant designed to manage heart failure issues, called the Cordella pulmonary artery sensor.
In July 2024, Edwards made agreements with Affluent Medical for an equity stake, IP licensing and an exclusive option to acquire its Kephalios subsidiary. The same month, Edwards announced it would acquire Innovalve Bio Medical for approximately $300 million, and JenaValve Technology and Endotronix for $1.2 billion.
In August 2024, Edwards acquired JC Medical from Genesis MedTech, gaining its J-Valve transcatheter aortic valve replacement system for the treatment of aortic regurgitation.
In 2023, Edwards announced that its critical care business unit would be spun off into a separate entity. In June 2024 Edwards instead agreed to sell the unit to BD for $4.2 billion. The sale closed on September 3, 2024.
In May 2025, the FDA approved the SAPIEN 3 platform, including the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, for the treatment of severe aortic stenosis in asymptomatic patients, marking the first FDA approval of TAVR therapy for this patient population.
In September 2025, Edwards completed the full acquisition of heart failure monitoring company Vectorious Medical Technologies.
In January 2026, the FDA approved the SAPIEN M3 mitral valve replacement system, the first transcatheter mitral valve replacement therapy using a transseptal approach to receive FDA approval for the treatment of mitral regurgitation.
Business segments
Prior to September 2024, its products were categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and critical care. In September 2024, Edwards completed the sale of its Critical Care product group to BD. Since September 2024, its products are categorized into four areas: surgical valve technologies, transcatheter heart valves, transcatheter mitral and tricuspid therapies, and implantable heart failure management (IHFM).
Transcatheter Heart Valve
The company's SAPIEN family of transcatheter aortic heart valves is made of bovine pericardial tissue mounted within a balloon-expandable, cobalt-chromium frame and is deployed via catheter. Edwards introduced the transcatheter heart valve replacement procedure to U.S. patients unable to undergo open-heart surgery with FDA approval of the SAPIEN transcatheter valve in 2011. The indication was expanded in November 2012 to include patients at a high risk for death or serious complications associated with open-heart surgery. In 2021, the FDA cleared Edwards’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement. In May 2024, Edwards launched the SAPIEN 3 Ultra RESILIA valve in Europe.
Transcatheter Mitral and Tricuspid Therapies
The Transcatheter Mitral and Tricuspid Therapies business segment develops transcatheter heart valve repair and replacement technologies to treat mitral and tricuspid valve diseases. In September 2022, the FDA approved Edwards' PASCAL Precision transcatheter valve repair system for the treatment of degenerative mitral regurgitation.
Surgical
The Surgical business segment involves the use of Edwards' RESILIA tissue technology, developed to help limit valve calcification. Edwards estimates that more than 450,000 patients around the world have either undergone SAVR or TAVR with an Edwards RESILIA valve.
Critical Care
Before its sale, the Critical Care business segment included pulmonary artery catheters, disposable pressure transducers and advanced hemodynamic monitoring systems. The portfolio also included a line of balloon catheter-based vascular products, surgical clips and inserts. In 2023, it was announced that the critical care business unit was to be spun off into its own entity, however in 2024 the critical care department was purchased by BD for $4.2 billion.
Organizational culture
Edwards Lifesciences Foundation
The Edwards Lifesciences Foundation launched in 2014 and supports programs designed to treat underserved people to reduce heart valve disease.
Since the initiative launched in 2014, Edwards and its foundation have contributed more than $100 million in financial and technology donations through "Every Heartbeat Matters" (EHM), reaching over 4 million underserved structural heart patients globally.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
EW Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$91.21
Capitalizzazione di Mercato
$60.20B
P/E (TTM)
56.6
EPS (TTM)
$1.83
Ricavi (TTM)
$6.07B
Rendimento div.
—
ROE
10.6%
D/E Debito/Patrimonio
0.1
Intervallo 52 sett.
$72 – $96
EW Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$6.07B
2016-12-31
→
2025-12-31
EPS
$1.83
2016-12-31
→
2025-12-31
Flusso di cassa libero
$1.33B
2016-12-31
→
2025-12-31
Margini
17.7%
2016-12-31
→
2025-12-31
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
EW
Mediana dei peer
P/E (TTM)
56.6
26.3
P/S (TTM)
9.9
4.4
P/B
5.8
5.3
EV / EBITDA
39.8
—
Price / FCF (Prezzo / FCF)
45.1
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
EW
Mediana dei peer
Gross Margin (Margine lordo)
78.0%
63.1%
Operating Margin (Margine Operativo)
20.8%
—
Net Profit Margin (Margine di Profitto Netto)
17.7%
15.6%
ROA
8.0%
7.6%
ROE
10.6%
15.0%
ROIC
9.6%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
EW
Mediana dei peer
Debt / Equity (Debito / Patrimonio Netto)
0.1
—
Current Ratio (Rapporto corrente)
3.7
1.7
Quick Ratio
2.7
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
EW
Mediana dei peer
Revenue YoY (Ricavi YoY)
11.6%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
10.8%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
6.7%
—
EPS YoY
-73.7%
—
Net Income YoY (Utile Netto YoY)
-74.3%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
EW
Mediana dei peer
EW Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
40 analisti
- Acquisto forte 13 32,5%
- Compra 17 42,5%
- Mantieni 10 25,0%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
26 analisti · 2026-08-19
Mediana
$101.50
Ora
$91.21
Basso
$84.00
Alto
$110.00
Target mediano
$101.50
+11,3%
Target medio
$100.96
+10,7%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
0.02%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $0.78 | $0.76 | 0.02% |
| 31 Marzo 2026 | $0.78 | $0.75 | 0.03% |
| 31 Dicembre 2025 | $0.58 | $0.64 | -0.06% |
| 30 Settembre 2025 | $0.67 | $0.61 | 0.06% |
| 30 Giugno 2025 | $0.67 | $0.64 | 0.03% |
| 31 Marzo 2025 | $0.64 | $0.61 | 0.03% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | — |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | — | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| BDX | — | 25.3 | 8.2% | 7.7% | 6.5% | — |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| GEHC | — | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Cost of Revenue | $1.33B | $1.12B | $978M | $724M | $1.25B | $1.08B | $1.11B | $939M | $875M | $797M | $617M | $626M | |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B | $2.56B | $2.17B | $1.88B | $1.70B | |
| R&D Expense | $1.08B | $1.05B | $963M | $844M | $903M | $761M | $753M | $622M | $553M | $442M | $383M | $346M | |
| SG&A Expense | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | $1.23B | $1.24B | $1.09B | $991M | $905M | $851M | $858M | |
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $898M | $1.15B | $748M | $1.09B | $751M | · | · | |
| Interest Expense | · | · | $18M | $19M | $18M | $16M | $21M | $30M | $23M | $19M | $17M | $17M | |
| Interest Income | $169M | $120M | $67M | $36M | $17M | $23M | $32M | $32M | $20M | $11M | $8M | $6M | |
| Other Non-op | $7M | $69M | $14M | $5M | $13M | $12M | $8M | $4M | $-1M | $-5M | $-4M | $-8M | |
| Pretax Income | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | $917M | $1.17B | $761M | $1.03B | $738M | $622M | $1.14B | |
| Income Tax | $217M | $152M | $152M | $196M | $199M | $93M | $120M | $39M | $451M | $168M | $128M | $333M | |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | · | · | · | · | · | · | · | |
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 | $2.77 | $2.67 | $2.30 | $3.81 | |
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 | $2.70 | $2.61 | $2.25 | $3.74 | |
| Shares (Basic) | 584,800,000 | 597,700,000 | 606,700,000 | 619,000,000 | 623,300,000 | 622,600,000 | 624,800,000 | 627,600,000 | 210,900,000 | 213,000,000 | 215,500,000 | 213,000,000 | |
| Shares (Diluted) | 585,800,000 | 599,300,000 | 609,400,000 | 624,200,000 | 631,200,000 | 631,900,000 | 636,700,000 | 640,900,000 | 215,900,000 | 217,800,000 | 220,300,000 | 217,000,000 | |
| EBITDA | $1.42B | $1.53B | $1.68B | $1.89B | $1.83B | $1.00B | $1.24B | $826M | $82M | $71M | $66M | $69M |
Stato Patrimoniale 29
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.94B | $3.05B | $1.13B | $769M | $863M | $1.18B | $1.18B | $714M | $818M | $930M | $718M | $654M | |
| Short-term Investments | $1.29B | $931M | $500M | $446M | $604M | $219M | $338M | $242M | $519M | $341M | $506M | $785M | |
| Receivables | $660M | $609M | $772M | $643M | $582M | $515M | $544M | $457M | $439M | $366M | $315M | $288M | |
| Inventory | $1.13B | $1.09B | $904M | $876M | $727M | $802M | $641M | $607M | $555M | $397M | $340M | $297M | |
| Prepaid Expense | $135M | $121M | $129M | $110M | $85M | $75M | $59M | $54M | $61M | $46M | $45M | $49M | |
| Other Current Assets | $339M | $348M | $225M | $196M | $237M | $208M | $168M | $132M | $117M | $112M | $66M | $122M | |
| Current Assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B | $2.55B | $2.24B | $2.05B | $2.23B | |
| PP&E (Net) | $1.81B | $1.69B | $1.59B | $1.63B | $1.55B | $1.40B | $1.06B | $868M | $680M | $580M | $482M | $443M | |
| PP&E (Gross) | $2.66B | $2.48B | $2.29B | $2.38B | $2.20B | $1.99B | $1.57B | $1.32B | $1.09B | $961M | $854M | $808M | |
| Accum. Depreciation | $850M | $794M | $699M | $750M | $655M | $598M | $512M | $455M | $412M | $381M | $372M | $365M | |
| Goodwill | $1.77B | $1.78B | $1.15B | $1.06B | $1.17B | $1.17B | $1.17B | $1.11B | $1.13B | $626M | $628M | $376M | |
| Intangibles | $1.13B | $1.18B | $399M | $285M | $324M | $331M | $336M | $343M | $468M | $205M | $205M | $23M | |
| Other Non-current Assets | $730M | $722M | $463M | $299M | $111M | $120M | $102M | $34M | $109M | $123M | $132M | $49M | |
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Accounts Payable | $228M | $197M | $187M | $202M | $204M | $196M | $180M | $134M | $117M | $97M | $64M | $58M | |
| Current Liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B | $894M | $902M | $877M | $1.42B | $532M | $476M | $426M | |
| Capital Leases | $83M | $79M | $65M | $70M | $69M | $73M | $59M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $37M | · | · | · | · | · | |
| Other Non-current Liabilities | $362M | $373M | $251M | $218M | $267M | $252M | $203M | $150M | $147M | $115M | $285M | $113M | |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $594M | $1.04B | $822M | · | · | |
| Total Debt | $598M | $598M | $597M | $596M | $596M | $595M | $594M | $594M | $1.04B | $822M | $600M | $598M | |
| Common Stock | $659M | $655M | $650M | $646M | $642M | $636M | $218M | $215M | $212M | $243M | $239M | $129M | |
| Retained Earnings | $14.24B | $13.17B | $8.99B | $7.59B | $6.07B | $4.57B | $3.74B | $2.69B | $1.96B | $3.91B | $3.34B | $2.84B | |
| Treasury Stock | $7.09B | $6.19B | $5.02B | $4.14B | $2.42B | $1.90B | $1.28B | $1.02B | $252M | $2.50B | $1.84B | $1.56B | |
| AOCI | $-238M | $-244M | $-243M | $-255M | $-158M | $-161M | $-156M | $-138M | $-133M | $-198M | $-183M | $-101M | |
| Stockholders' Equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B | $2.96B | $2.62B | $2.50B | $2.19B | |
| Liabilities + Equity | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B | $5.67B | $4.51B | $4.06B | $3.52B | |
| Shares Outstanding | 580,700,000 | 654,800,000 | 650,500,000 | 646,300,000 | 642,000,000 | 636,400,000 | 218,100,000 | 207,700,000 | 209,700,000 | 211,600,000 | 215,400,000 | 107,800,000 |
Flusso di cassa 18
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $157M | $155M | $145M | $140M | $135M | $107M | $89M | $77M | $82M | $71M | $66M | $69M | |
| Stock-based Comp | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M | $50M | $48M | |
| Deferred Tax | $-66M | $-163M | $-242M | $-262M | $-44M | $-52M | $10M | $-21M | $27M | $-24M | $-16M | $-67M | |
| Amort. of Intangibles | $8M | $6M | $2M | $2M | $8M | $5M | $5M | $2M | $8M | $8M | $7M | $8M | |
| Restructuring | $13M | $33M | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-cash | $273M | $-3.79B | $-529M | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $1.60B | $542M | $896M | $1.22B | $1.73B | $1.05B | $1.18B | $927M | $1.00B | $704M | $550M | $1.02B | |
| CapEx | $260M | $252M | $253M | $245M | $326M | $407M | $254M | $239M | $168M | $176M | $103M | $83M | |
| Investing Cash Flow | $-713M | $2.31B | $174M | $252M | $-1.72B | $-531M | $-596M | $77M | $-647M | $-212M | $-316M | · | |
| Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Net Debt Issued | · | · | $0 | $0 | $5M | $16M | $19M | $688M | $995M | $254M | $31M | $226M | |
| Stock Repurchased | $893M | $1.16B | $880M | $1.73B | $513M | $625M | $263M | $796M | $763M | $662M | $280M | $301M | |
| Net Stock Activity | $-893M | $-1.16B | $-880M | $-1.73B | $-513M | $-625M | $-263M | $-796M | $-763M | $-662M | $-280M | $-301M | |
| Financing Cash Flow | $-957M | $-983M | $-711M | $-1.58B | $-356M | $-487M | $-116M | $-1.10B | $-473M | $-268M | $-159M | · | |
| Net Change in Cash | $-119M | $1.91B | $375M | $-95M | $-333M | $16M | $468M | $-104M | $-112M | $212M | $65M | $233M | |
| Taxes Paid | $490M | $1.20B | $470M | · | · | · | · | · | · | · | · | $275M | |
| Free Cash Flow | $1.33B | $290M | $643M | $974M | $1.41B | $647M | $925M | $688M | $833M | $528M | $447M | $939M | |
| Levered FCF | · | · | $627M | $957M | $1.39B | $633M | $906M | $660M | $820M | $513M | $433M | $927M |
Redditività 8
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% | 75.2% | 73.1% | |
| Operating Margin | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% | 20.5% | 26.4% | 20.1% | · | · | · | · | |
| Net Margin | 17.7% | 76.8% | 23.4% | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | 21.0% | 28.5% | 26.6% | 32.8% | 32.5% | 20.9% | 26.8% | 20.4% | 30.1% | 24.9% | 25.0% | 49.2% | |
| EBITDA Margin | 23.4% | 28.2% | 28.0% | 35.1% | 34.9% | 22.9% | 28.4% | 22.2% | 2.4% | 2.4% | 2.6% | 2.9% | |
| ROA | 8.0% | 37.2% | 15.9% | · | · | · | · | · | · | · | · | · | |
| ROE | 10.6% | 50.1% | 22.5% | · | · | · | · | · | · | · | · | · | |
| ROIC | 9.6% | 11.7% | 18.5% | 23.5% | 23.2% | 15.6% | 21.7% | 19.0% | · | · | · | · |
Liquidità e Solvibilità 5
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 | 3.5 | 3.3 | 2.6 | 1.8 | 4.2 | 4.3 | 5.3 | |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 | 2.1 | 2.3 | 1.6 | 1.3 | 3.1 | 3.2 | 4.0 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.3 | 0.2 | 0.3 | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.2 | 0.3 | |
| Interest Coverage | · | · | 87.2 | 91.1 | 91.9 | 56.8 | 55.4 | 25.0 | · | · | · | · |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.7 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | 1.2 | 1.1 | 1.4 | 1.3 | 1.6 | 1.5 | 1.8 | 1.6 | 1.8 | 2.2 | 1.9 | 2.1 | |
| Receivables Turnover | 9.6 | 7.9 | 8.5 | 8.8 | 9.5 | 8.3 | 8.7 | 8.3 | 8.7 | 8.7 | 8.3 | 7.9 |
Tassi di Crescita 8
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.6% | 8.6% | 12.2% | -14.7% | 19.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 10.8% | 1.3% | 4.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.7% | 203.0% | -5.7% | 2.5% | 83.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -9.1% | 43.1% | 20.9% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.3% | 197.7% | -7.8% | 1.2% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -11.0% | 40.6% | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B | $3.44B | $2.96B | $2.49B | $2.32B | |
| Net Income TTM | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $235M | $235M | $235M | $235M | $235M | $235M | $235M | |
| Market Cap | $49.50B | $43.57B | $45.83B | $45.39B | $80.85B | $56.95B | $16.26B | $10.60B | $7.88B | $6.61B | $5.67B | $2.29B | |
| Enterprise Value | $45.88B | $40.20B | $44.79B | $44.77B | $79.98B | $56.15B | $15.34B | $10.24B | $7.58B | $6.16B | $5.05B | $1.45B | |
| P/E | 46.6 | 10.6 | 33.2 | 30.6 | 54.4 | 70.2 | 47.4 | 45.2 | 13.9 | 12.0 | 11.7 | 5.7 | |
| P/S | 8.2 | 8.0 | 9.1 | 10.2 | 15.5 | 13.0 | 3.7 | 2.8 | 2.3 | 2.2 | 2.3 | 1.0 | |
| P/B | 4.8 | 4.4 | 6.9 | 7.8 | 13.9 | 12.5 | 3.9 | 3.4 | 2.7 | 2.5 | 2.3 | 1.0 | |
| P / Tangible Book | 6.7 | 6.2 | 9.0 | 10.2 | 18.6 | 18.6 | · | · | · | · | · | · | |
| P / Cash Flow | 31.0 | 80.4 | 51.2 | 37.3 | 46.7 | 54.0 | 13.8 | 11.4 | 7.9 | 9.4 | 10.3 | 2.2 | |
| P / FCF | 37.1 | 150.3 | 71.3 | 46.6 | 57.5 | 88.0 | 17.6 | 15.4 | 9.5 | 12.5 | 12.7 | 2.4 | |
| EV / EBITDA | 32.3 | 26.2 | 26.7 | 23.7 | 43.8 | 55.9 | 12.4 | 12.4 | 92.5 | 86.5 | 76.7 | 21.1 | |
| EV / FCF | 34.4 | 138.7 | 69.7 | 46.0 | 56.9 | 86.7 | 16.6 | 14.9 | 9.1 | 11.7 | 11.3 | 1.5 | |
| EV / Revenue | 7.6 | 7.4 | 8.9 | 10.0 | 15.3 | 12.8 | 3.5 | 2.8 | 2.2 | 2.1 | 2.0 | 0.6 | |
| Earnings Yield | 2.1% | 9.4% | 3.0% | 3.3% | 1.8% | 1.4% | 2.1% | 2.2% | 7.2% | 8.4% | 8.6% | 17.6% |
Conto Economico 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B | $1.37B | $1.33B | $1.01B | $1.24B | $1.28B | $1.22B | $430M | $1.32B | |
| Cost of Revenue | $392M | $363M | $343M | $345M | $344M | $302M | $292M | $263M | $276M | $287M | $141M | $251M | $257M | $330M | $-99M | $254M | |
| Gross Profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B | $1.09B | $1.04B | $870M | $993M | $1.03B | $992M | $529M | $1.07B | |
| R&D Expense | $279M | $263M | $268M | $281M | $276M | $255M | $271M | $253M | $272M | $257M | $215M | $243M | $244M | $261M | $131M | $234M | |
| SG&A Expense | $561M | $522M | $603M | $515M | $502M | $466M | $492M | $421M | $448M | $428M | $354M | $382M | $410M | $436M | $201M | $377M | |
| Operating Income | $513M | $478M | $151M | $307M | $411M | $395M | $313M | $351M | $366M | $349M | $291M | $366M | $264M | $388M | $198M | $402M | |
| Interest Income | $30M | $34M | · | · | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-op | $17M | $72M | $3M | $3M | $-1M | $3M | $33M | $28M | $2M | $6M | $3M | $7M | $2M | $2M | $6M | $-2M | |
| Pretax Income | $520M | $459M | $90M | $348M | $400M | $434M | $390M | $403M | $384M | $371M | $311M | $388M | $275M | $399M | $211M | $407M | |
| Income Tax | $278M | $78M | $26M | $56M | $64M | $70M | $45M | $41M | $20M | $46M | $21M | $53M | $21M | $58M | $11M | $64M | |
| Net Income | $242M | $381M | $91M | $291M | $333M | $358M | $386M | $3.07B | $366M | $352M | $370M | $385M | $307M | $340M | $398M | $344M | |
| EPS (Basic) | $0.42 | $0.66 | $0.16 | $0.50 | $0.57 | $0.61 | $0.65 | $5.14 | $0.61 | $0.58 | $0.61 | $0.63 | $0.51 | $0.56 | $0.66 | $0.55 | |
| EPS (Diluted) | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 | $0.61 | $0.58 | $0.61 | $0.63 | $0.50 | $0.56 | $0.65 | $0.55 | |
| Shares (Basic) | 576,400,000 | 579,200,000 | -1,173,800,000 | 584,700,000 | 587,000,000 | 586,900,000 | -1,203,200,000 | 597,200,000 | 602,100,000 | 601,600,000 | -1,214,700,000 | 607,000,000 | 606,900,000 | 607,500,000 | -1,243,800,000 | 619,800,000 | |
| Shares (Diluted) | 577,600,000 | 580,700,000 | -1,175,600,000 | 585,700,000 | 587,900,000 | 587,800,000 | -1,207,200,000 | 598,100,000 | 604,300,000 | 604,100,000 | -1,221,300,000 | 609,500,000 | 610,300,000 | 610,900,000 | -1,256,400,000 | 624,500,000 | |
| EBITDA | $513M | $518M | · | $307M | $411M | $431M | · | $351M | $369M | $426M | · | $418M | $327M | $424M | · | $402M |
Stato Patrimoniale 27
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.91B | $2.45B | $2.94B | $2.69B | $3.27B | $3.14B | $3.05B | $3.68B | $1.64B | $1.22B | · | $1.41B | $1.04B | $872M | · | $1.25B | |
| Short-term Investments | $1.35B | $1.23B | $1.29B | $1.16B | $789M | $758M | $931M | $770M | $345M | $473M | · | $454M | $467M | $382M | · | $491M | |
| Receivables | $770M | $776M | $660M | $693M | $697M | $669M | $609M | $716M | $778M | $818M | · | $740M | $754M | $718M | · | $618M | |
| Inventory | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | $1.11B | $1.09B | $1.10B | $1.02B | $1.21B | · | $1.03B | $980M | $914M | · | $758M | |
| Prepaid Expense | $119M | $136M | $135M | $125M | $110M | $111M | $121M | $115M | $110M | $138M | · | $133M | $123M | $119M | · | $88M | |
| Other Current Assets | $360M | $330M | $339M | $323M | $314M | $304M | $348M | $231M | $252M | $251M | · | $236M | $217M | $190M | · | $268M | |
| Current Assets | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | $6.21B | $6.29B | $6.73B | $4.52B | $4.17B | · | $4.07B | $3.65B | $3.26B | · | $3.51B | |
| PP&E (Net) | $1.84B | $1.82B | $1.81B | $1.74B | $1.73B | $1.70B | $1.69B | $1.68B | $1.64B | $1.77B | · | $1.68B | $1.66B | $1.65B | · | $1.57B | |
| PP&E (Gross) | · | · | $2.66B | · | · | · | $2.48B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $850M | · | · | · | $794M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $1.95B | $1.82B | $1.77B | $1.77B | $1.78B | $1.78B | $1.78B | $1.61B | $1.15B | $1.25B | $1.15B | $1.30B | $1.30B | $1.31B | $1.06B | $1.16B | |
| Intangibles | $1.38B | $1.23B | $1.13B | $1.13B | $1.17B | $1.17B | $1.18B | $956M | $417M | $447M | · | $430M | $431M | $447M | · | $266M | |
| Other Non-current Assets | $616M | $739M | $730M | $785M | $743M | $743M | $722M | $684M | $790M | $768M | · | $447M | $412M | $294M | · | $316M | |
| Total Assets | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Accounts Payable | $210M | $181M | $228M | $165M | $162M | $172M | $197M | $173M | $186M | $212M | · | $191M | $193M | $181M | · | $155M | |
| Current Liabilities | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | $1.39B | $1.51B | $1.94B | $1.22B | $1.11B | · | $1.24B | $1.16B | $1.08B | · | $918M | |
| Capital Leases | $82M | $80M | $83M | $75M | $79M | $78M | $79M | $85M | $74M | $77M | · | $70M | $64M | $66M | · | $67M | |
| Other Non-current Liabilities | $382M | $351M | $362M | $363M | $379M | $358M | $373M | $323M | $257M | $266M | · | $240M | $243M | $260M | · | $221M | |
| Total Liabilities | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B | $3.36B | $2.59B | $2.55B | · | $2.64B | $2.56B | $2.59B | · | $2.42B | |
| Total Debt | $599M | $598M | · | $598M | $598M | $598M | · | $598M | $597M | $597M | · | $597M | $597M | $596M | · | $596M | |
| Common Stock | $662M | $660M | $659M | $658M | $658M | $656M | $655M | $654M | $654M | $652M | · | $650M | $649M | $647M | · | $646M | |
| Retained Earnings | $14.86B | $14.62B | $14.24B | $14.15B | $13.86B | $13.53B | $13.17B | $12.78B | $9.71B | $9.34B | · | $8.62B | $8.24B | $7.93B | · | $7.19B | |
| Treasury Stock | $7.67B | $7.51B | $7.09B | $7.05B | $6.46B | $6.45B | $6.19B | $6.09B | $5.18B | $5.02B | · | $4.58B | $4.40B | $4.39B | · | $3.28B | |
| AOCI | $-215M | $-221M | $-238M | $-250M | $-264M | $-254M | $-244M | $-252M | $-220M | $-233M | · | $-250M | $-256M | $-255M | · | $-256M | |
| Stockholders' Equity | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B | $9.55B | $7.44B | $7.12B | · | $6.66B | $6.38B | $5.98B | · | $6.22B | |
| Liabilities + Equity | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B | $12.97B | $10.10B | $9.74B | · | $9.37B | $9.00B | $8.65B | · | $8.64B | |
| Shares Outstanding | 576,600,000 | 577,000,000 | 580,700,000 | 580,700,000 | 587,900,000 | 586,200,000 | 588,600,000 | 589,800,000 | 602,300,000 | 602,400,000 | 650,500,000 | 606,500,000 | 607,900,000 | 606,000,000 | 646,300,000 | 619,400,000 |
Flusso di cassa 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $43M | $41M | $43M | $39M | $38M | $37M | $43M | $34M | $40M | $38M | $37M | $37M | $36M | $35M | $35M | $35M | |
| Stock-based Comp | $42M | $45M | $39M | $41M | $38M | $40M | $32M | $42M | $44M | $45M | $30M | $33M | $37M | $39M | $28M | $30M | |
| Restructuring | · | · | $5M | $100.0K | · | · | $0 | $33M | · | · | · | $0 | · | · | · | · | |
| Other Non-cash | · | $-423M | · | · | · | $-154M | · | · | · | $-488M | · | · | · | · | · | · | |
| Operating Cash Flow | $652M | $44M | $451M | $574M | $290M | $280M | $-128M | $352M | $372M | $-54M | $137M | $412M | $34M | $314M | $283M | $310M | |
| CapEx | $67M | $65M | $97M | $58M | $49M | $56M | $50M | $52M | $85M | $65M | $88M | $55M | $48M | $62M | $69M | $60M | |
| Investing Cash Flow | $-193M | $-93M | $-198M | $-428M | $-172M | $85M | $-577M | $2.70B | $125M | $63M | $14M | $89M | $70M | $500.0K | $95M | $-202M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | $153M | $422M | $41M | $589M | $6M | $259M | $100M | $901M | $158M | $200.0K | $448M | $174M | $8M | $249M | $866M | $100M | |
| Net Stock Activity | · | $-422M | · | · | · | $-259M | · | · | · | $-200.0K | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-300.0K | $-451M | $-11M | $-740M | $53M | $-258M | $29M | $-977M | $-97M | $62M | $-413M | $-143M | $52M | $-207M | $-838M | $-70M | |
| Net Change in Cash | $462M | $-492M | $245M | $-595M | $141M | $90M | $-625M | $2.03B | $429M | $81M | $-266M | $366M | $171M | $104M | $-479M | $49M | |
| Free Cash Flow | · | $-21M | · | · | · | $224M | · | · | · | $-119M | · | · | · | $253M | · | · |
Redditività 8
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 78.0% | · | 77.8% | 77.5% | 78.6% | · | 80.6% | 79.4% | 75.9% | · | 76.3% | 77.6% | 77.4% | · | 80.8% | |
| Operating Margin | 29.5% | 29.0% | · | 19.8% | 26.8% | 28.0% | · | 25.9% | 26.6% | 24.2% | · | 28.2% | 21.4% | 26.6% | · | 30.5% | |
| Net Margin | 13.9% | 23.1% | · | 18.7% | 21.8% | 25.3% | · | 226.7% | 26.4% | 22.0% | · | 26.0% | 20.1% | · | · | · | |
| Pretax Margin | 29.9% | 27.8% | · | 22.4% | 26.1% | 30.7% | · | 29.7% | 27.9% | 25.6% | · | 29.7% | 22.1% | 27.3% | · | 30.9% | |
| EBITDA Margin | 29.5% | 31.4% | · | 19.8% | 26.8% | 30.5% | · | 25.9% | 26.6% | 26.7% | · | 28.2% | 21.4% | 29.0% | · | 30.5% | |
| ROA | 1.8% | 2.9% | · | 2.2% | 2.8% | 3.1% | · | 27.5% | 3.8% | 3.8% | · | 4.3% | 3.5% | · | · | · | |
| ROE | 2.3% | 3.7% | · | 2.9% | 3.7% | 4.2% | · | 37.9% | 5.3% | 5.4% | · | 6.0% | 5.0% | · | · | · | |
| ROIC | 2.1% | 3.6% | · | 2.4% | 3.1% | 3.1% | · | 3.1% | 4.3% | 4.3% | · | 5.0% | 4.2% | 5.1% | · | 5.0% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 4.4 | · | 4.0 | 4.7 | 4.5 | · | 3.5 | 3.7 | 3.8 | · | 3.3 | 3.2 | 3.0 | · | 3.8 | |
| Quick Ratio | 3.3 | 3.2 | · | 2.9 | 3.4 | 3.3 | · | 2.7 | 2.3 | 2.3 | · | 2.1 | 2.0 | 1.8 | · | 2.6 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | 2.4 | 2.3 | · | 2.2 | 2.1 | 1.9 | · | 1.9 | 1.8 | 2.1 | · | 2.2 | 2.2 | 2.2 | · | 2.2 |
Valutazione (TTM) 14
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6.47B | $6.15B | · | $5.88B | $5.69B | $5.52B | · | $5.32B | $5.21B | $5.12B | · | $5.06B | $5.19B | $5.26B | · | $5.34B | |
| Net Income TTM | $1.25B | $1.36B | · | $1.37B | $4.15B | $4.18B | · | $4.16B | $1.47B | $1.41B | · | $1.38B | $1.40B | · | · | · | |
| Market Cap | $52.16B | $46.21B | · | $45.16B | $45.98B | $42.49B | · | $38.92B | $55.63B | $57.57B | · | $42.02B | $57.34B | $50.13B | · | $51.18B | |
| Enterprise Value | $48.51B | $43.13B | · | $41.92B | $42.52B | $39.19B | · | $35.07B | $54.24B | $56.46B | · | $40.75B | $56.43B | $49.48B | · | $50.04B | |
| P/E | 42.3 | 34.4 | · | 33.5 | 11.3 | 10.4 | · | 9.5 | 38.0 | 41.2 | · | 30.9 | 41.7 | 35.2 | · | 35.5 | |
| P/S | 8.1 | 7.5 | · | 7.7 | 8.1 | 7.7 | · | 7.3 | 10.7 | 11.2 | · | 8.3 | 11.0 | 9.5 | · | 9.6 | |
| P/B | 4.9 | 4.5 | · | 4.4 | 4.4 | 4.2 | · | 4.1 | 7.5 | 8.1 | · | 6.3 | 9.0 | 8.4 | · | 8.2 | |
| P / Tangible Book | 7.2 | 6.3 | · | 6.2 | 6.1 | 5.9 | · | 5.6 | 9.5 | 10.6 | · | 8.5 | 12.3 | 11.9 | · | 10.7 | |
| P / Cash Flow | · | 1054.9 | · | · | · | 151.5 | · | · | · | -1076.0 | · | · | · | 159.6 | · | · | |
| P / FCF | · | -2189.9 | · | · | · | 189.3 | · | · | · | -484.6 | · | · | · | 198.5 | · | · | |
| EV / EBITDA | 94.5 | 83.2 | · | 136.5 | 103.4 | 90.8 | · | 100.0 | 147.0 | 132.5 | · | 97.4 | 172.5 | 116.8 | · | 124.4 | |
| EV / FCF | · | -2044.2 | · | · | · | 174.6 | · | · | · | -475.3 | · | · | · | 195.9 | · | · | |
| EV / Revenue | 7.5 | 7.0 | · | 7.1 | 7.5 | 7.1 | · | 6.6 | 10.4 | 11.0 | · | 8.0 | 10.9 | 9.4 | · | 9.4 | |
| Earnings Yield | 2.4% | 2.9% | · | 3.0% | 8.9% | 9.7% | · | 10.5% | 2.6% | 2.4% | · | 3.2% | 2.4% | 2.8% | · | 2.8% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Margine Lordo % | 78.0% | 79.5% | 77.0% | 79.9% | 76.1% |
| Margine Operativo % | 20.8% | 25.4% | 25.6% | 32.5% | 32.3% |
| Utile netto | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| EPS Diluito | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Debito / Patrimonio Netto | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Rapporto corrente | 3.7 | 4.2 | 3.4 | 3.0 | 3.1 |
| Quick Ratio | 2.7 | 3.0 | 2.0 | 1.8 | 2.0 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $1.33B | $290M | $643M | $974M | $1.41B |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 1.442 filer · $30.2B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 152 (+6 vs trimestre precedente) | 97 (-10 vs trimestre precedente) | 459 (+11 vs trimestre precedente) | 452 (+4 vs trimestre precedente) | +26.4M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3.402.739.018 | 37.615.952 | 11,25% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.389.175.425 | 26.411.402 | 7,90% | Azioni |
| STATE STREET CORP | $2.381.082.692 | 26.321.940 | 7,87% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $1.430.999.585 | 15.819.142 | 4,73% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $1.219.437.867 | 13.541.730 | 4,03% | Azioni |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $1.135.640.991 | 12.554.068 | 3,75% | Azioni |
| Ninety One UK Ltd | $1.116.050.276 | 12.337.502 | 3,69% | Azioni |
| Aristotle Capital Management, LLC | $783.906.442 | 8.665.712 | 2,59% | Azioni |
| NORGES BANK | $757.492.410 | 8.373.783 | 2,50% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $693.526.113 | 8.660.416 | 2,29% | Azioni |
| FMR LLC | $607.177.379 | 6.712.109 | 2,01% | Azioni |
| Artisan Partners Limited Partnership | $599.361.052 | 6.625.703 | 1,98% | Azioni |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $513.572.538 | 5.677.344 | 1,70% | Azioni |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | $434.208.000 | 4.800.000 | 1,44% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $334.052.859 | 3.692.824 | 1,10% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $324.280.556 | 3.584.795 | 1,07% | Azioni |
| CITADEL ADVISORS LLC | $308.338.066 | 3.408.557 | 1,02% | Azioni |
| PRIMECAP MANAGEMENT CO/CA/ | $308.314.004 | 3.408.291 | 1,02% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $298.865.427 | 3.303.843 | 0,99% | Azioni |
| BROWN ADVISORY INC | $295.062.880 | 3.261.805 | 0,98% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $292.399.738 | 3.232.365 | 0,97% | Azioni |
| Holocene Advisors, LP | $283.979.721 | 3.139.285 | 0,94% | Azioni |
| NEUBERGER BERMAN GROUP LLC | $255.069.412 | 2.818.763 | 0,84% | Azioni |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $250.776.107 | 2.772.232 | 0,83% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $238.277.000 | 2.634.054 | 0,79% | Azioni |
| Mirova US LLC | $229.802.865 | 2.540.381 | 0,76% | Azioni |
| BANK OF AMERICA CORP /DE/ | $170.884.489 | 1.889.061 | 0,56% | Azioni |
| BlackRock, Inc. | $168.018.323 | 1.857.377 | 0,56% | Azioni |
| Assenagon Asset Management S.A. | $163.997.286 | 1.812.926 | 0,54% | Azioni |
| Point72 Asset Management, L.P. | $160.486.895 | 1.774.120 | 0,53% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $152.806.000 | 1.689.211 | 0,51% | Azioni |
| Swiss National Bank | $147.097.006 | 1.626.100 | 0,49% | Azioni |
| Woodline Partners LP | $141.123.209 | 1.560.062 | 0,47% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $140.351.128 | 1.551.434 | 0,46% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $137.670.984 | 1.521.899 | 0,46% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $131.472.173 | 1.453.357 | 0,43% | Azioni |
| Mitsubishi UFJ Asset Management Co., Ltd. | $126.120.870 | 1.394.217 | 0,42% | Azioni |
| Legal & General Group Plc | $121.108.845 | 1.338.811 | 0,40% | Azioni |
| ROYAL BANK OF CANADA | $119.193.000 | 1.317.637 | 0,39% | Azioni |
| Sumitomo Mitsui Trust Group, Inc. | $113.885.341 | 1.258.958 | 0,38% | Azioni |
| Quantinno Capital Management LP | $113.292.795 | 1.252.407 | 0,37% | Azioni |
| Vanguard Global Advisers, LLC | $112.247.472 | 1.240.852 | 0,37% | Azioni |
| VANGUARD GROUP INC | $107.656.172 | 1.262.829 | 0,36% | Azioni |
| SEB Asset Management AB | $106.981.085 | 1.182.636 | 0,35% | Azioni |
| Liontrust Investment Partners LLP | $106.083.480 | 1.244.381 | 0,35% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $100.522.409 | 1.111.236 | 0,33% | Azioni |
| Polar Capital Holdings Plc | $99.945.636 | 1.104.860 | 0,33% | Azioni |
| RHUMBLINE ADVISERS | $99.213.696 | 1.096.770 | 0,33% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $92.822.996 | 1.026.122 | 0,31% | Azioni |
| PARNASSUS INVESTMENTS, LLC | $91.873.890 | 1.015.630 | 0,30% | Azioni |
| Bank of New York Mellon Corp | $91.654.072 | 1.013.200 | 0,30% | Azioni |
| National Pension Service | $90.349.187 | 998.775 | 0,30% | Azioni |
| California Public Employees Retirement System | $89.091.250 | 984.869 | 0,29% | Azioni |
| Caisse de depot et placement du Quebec | $87.523.397 | 967.537 | 0,29% | Azioni |
| ABN AMRO Bank N.V. | $83.573.385 | 924.314 | 0,28% | Azioni |
| GOLDMAN SACHS GROUP INC | $82.454.109 | 911.498 | 0,27% | Azioni |
| Empower Advisory Group, LLC | $80.384.543 | 888.620 | 0,27% | Azioni |
| Meridiem Capital Partners LP | $77.697.994 | 858.921 | 0,26% | Azioni |
| Man Group plc | $76.372.212 | 844.265 | 0,25% | Azioni |
| ORBIMED ADVISORS LLC | $75.525.054 | 834.900 | 0,25% | Azioni |
| Alyeska Investment Group, L.P. | $73.531.316 | 812.860 | 0,24% | Azioni |
| Nantahala Capital Management, LLC | $72.368.000 | 800.000 | 0,24% | Opzione Put |
| CANADA PENSION PLAN INVESTMENT BOARD | $72.254.020 | 798.740 | 0,24% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $69.805.736 | 871.700 | 0,23% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $66.940.606 | 740.002 | 0,22% | Azioni |
| Bellevue Group AG | $66.871.108 | 739.234 | 0,22% | Azioni |
| Birch Hill Investment Advisors LLC | $66.522.203 | 735.377 | 0,22% | Azioni |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $64.772.074 | 716.030 | 0,21% | Azioni |
| TD Asset Management Inc | $61.560.472 | 680.527 | 0,20% | Azioni |
| PRINCIPAL FINANCIAL GROUP INC | $61.491.904 | 679.769 | 0,20% | Azioni |
| UBS Group AG | $60.908.889 | 673.324 | 0,20% | Azioni |
| Candriam S.C.A. | $59.988.129 | 663.784 | 0,20% | Azioni |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $57.604.363 | 675.711 | 0,19% | Azioni |
| Integral Health Asset Management, LLC | $56.537.500 | 625.000 | 0,19% | Azioni |
| Ninety One North America, Inc. | $55.768.413 | 616.498 | 0,18% | Azioni |
| Robeco Institutional Asset Management B.V. | $55.270.246 | 610.991 | 0,18% | Azioni |
| Seilern Investment Management Ltd | $54.296.896 | 600.231 | 0,18% | Azioni |
| Nan Shan Life Insurance Co., Ltd. | $49.953.912 | 552.221 | 0,17% | Azioni |
| PFA Pension, Forsikringsaktieselskab | $49.175.025 | 543.611 | 0,16% | Azioni |
| BARCLAYS PLC | $49.135.520 | 543.174 | 0,16% | Azioni |
| Triodos Investment Management BV | $44.629.165 | 493.358 | 0,15% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $44.266.149 | 489.345 | 0,15% | Azioni |
| Mitsubishi UFJ Trust & Banking Corp | $43.182.890 | 477.370 | 0,14% | Azioni |
| APG Asset Management N.V. | $42.840.046 | 541.444 | 0,14% | Azioni |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $42.480.287 | 469.603 | 0,14% | Azioni |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $42.097.461 | 465.371 | 0,14% | Azioni |
| AVIVA PLC | $41.577.497 | 459.623 | 0,14% | Azioni |
| Balyasny Asset Management L.P. | $41.248.584 | 455.987 | 0,14% | Azioni |
| Korea Investment CORP | $40.486.097 | 447.558 | 0,13% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $39.585.296 | 437.600 | 0,13% | Opzione Call |
| NORDEA INVESTMENT MANAGEMENT AB | $37.761.927 | 418.322 | 0,12% | Azioni |
| STOREBRAND ASSET MANAGEMENT AS | $37.671.343 | 416.442 | 0,12% | Azioni |
| Qube Research & Technologies Ltd | $37.490.061 | 414.438 | 0,12% | Azioni |
| OFI INVEST ASSET MANAGEMENT | $36.480.086 | 458.427 | 0,12% | Azioni |
| Fisher Funds Management LTD | $35.971.057 | 397.646 | 0,12% | Azioni |
| LPL Financial LLC | $34.985.891 | 386.755 | 0,12% | Azioni |
| ABN AMRO INVESTMENT SOLUTIONS | $33.668.217 | 372.189 | 0,11% | Azioni |
| AMERIPRISE FINANCIAL INC | $32.517.021 | 359.463 | 0,11% | Azioni |
| BLAIR WILLIAM & CO/IL | $32.206.687 | 356.032 | 0,11% | Azioni |
| Champlain Investment Partners, LLC | $31.357.054 | 346.640 | 0,10% | Azioni |
Insider aziendali 48 insider · 18 dirigenti · 8 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Bernard J Zovighian | CEO | 27 Luglio 2026 S | 8.916 | 0 | 8 | $-6.996.971 |
| Theodora Mistras | CVP, Chief Financial Officer | 09 Luglio 2026 A | 99.920 | 0 | 0 | $0 |
| Thomas M Abate | CVP, CFO | 14 Maggio 2013 A | 43.047 | 0 | 0 | $0 |
| Wayne Markowitz | CVP, JAPAC | 30 Luglio 2026 S | 21.534 | 0 | 4 | $-928.942 |
| Annette Bruls | CVP, EMEACLA | 11 Luglio 2026 F | 20.628 | 0 | 0 | $0 |
| Andrew M. Dahl | SVP, Corporate Controller | 29 Maggio 2026 S | 15.334 | 0 | 1 | $-48.893 |
| Carlyn D Solomon | CVP, Critical Care & Vascular | 28 Ottobre 2014 M | 31.154 | 0 | 0 | $0 |
| Christine Z Mccauley | CVP, Human Resources | 13 Maggio 2013 F | 4.035 | 0 | 0 | $0 |
| Paul C Redmond | CVP, Global Operations | 13 Maggio 2013 S | 12.534 | 0 | 0 | $0 |
| Bruce P Garren | CVP, Public Affairs/Special Co | 13 Maggio 2013 F | 56.071 | 0 | 0 | $0 |
| John H Kehl JR | CVP, Strategy & Corp Dev | 07 Maggio 2013 F | 101.767 | 0 | 0 | $0 |
| Robert C Reindl | CVP, H.R. and Communications | 27 Luglio 2012 M | 1.124 | 0 | 0 | $0 |
| Aimee S Weisner | CVP, General Counsel | 09 Maggio 2012 A | 1.675 | 0 | 0 | $0 |
| Corinne H Nevinny | CVP & Pres., Global Ops | 13 Maggio 2010 A | 16.687 | 0 | 0 | $0 |
| Anita Bessler | CVP | 31 Agosto 2007 S | 29.410 | 0 | 0 | $0 |
| John Alexander Martin | CVP, North America | 10 Maggio 2007 A | 15.300 | 0 | 0 | $0 |
| Stuart L Foster | CVP, Critical Care / Vascular | 10 Maggio 2007 A | 24.604 | 0 | 0 | $0 |
| Randel William Woodgrift | Corp VP, Manufacturing Ops | 04 Agosto 2005 M | 3.349 | 0 | 0 | $0 |
| John T Cardis | Direttore | 10 Agosto 2016 S | 91.458 | 0 | 0 | $0 |
| Barbara J Mcneil | Direttore | 04 Febbraio 2016 S | 46.454 | 0 | 0 | $0 |
| Robert Alexander Ingram | Direttore | 15 Maggio 2015 A | 32.367 | 0 | 0 | $0 |
| Michael R Bowlin | Direttore | 14 Novembre 2014 M | 81.751 | 0 | 0 | $0 |
| David E I Pyott | Direttore | 09 Maggio 2014 A | 53.582 | 0 | 0 | $0 |
| NEAL PHILIP M | Direttore | 12 Agosto 2008 M | 27.333 | 0 | 0 | $0 |
| Vernon R Loucks JR | Direttore | 09 Maggio 2008 A | 24.133 | 0 | 0 | $0 |
| Daniel J. Lippis | — | 11 Agosto 2026 M | 40.034 | 0 | 12 | $-817.452 |
| Donald E Bobo JR | — | 27 Maggio 2026 S | 98.611 | 0 | 12 | $-11.153.294 |
| Daveen Chopra | — | 22 Maggio 2026 S | 44.324 | 0 | 3 | $-500.535 |
| Scott B. Ullem | — | 11 Maggio 2026 M | 46.740 | 0 | 7 | $-3.875.008 |
| Leslie C. Davis | — | 08 Maggio 2026 A | 9.834 | 0 | 0 | $0 |
| Ramona Sequeira | — | 08 Maggio 2026 A | 6.779 | 0 | 0 | $0 |
| David T Feinberg | — | 08 Maggio 2026 A | 9.087 | 0 | 0 | $0 |
| Kieran Gallahue | — | 08 Maggio 2026 A | 4.315 | 0 | 0 | $0 |
| Nicholas J Valeriani | — | 08 Maggio 2026 A | 84.423 | 0 | 0 | $0 |
| Heisz Leslie Stone | — | 08 Maggio 2026 A | 34.199 | 0 | 1 | $-218.117 |
| Steven R Loranger | — | 08 Maggio 2026 A | 8.997 | 0 | 0 | $0 |
| Paul A Laviolette | — | 08 Maggio 2026 A | 17.552 | 0 | 0 | $0 |
| Larry L Wood | — | 18 Agosto 2025 M | 206.900 | 0 | 0 | $0 |
| Catherine M. Szyman | — | 03 Settembre 2024 F | 81.287 | 0 | 0 | $0 |
| Jean-Luc M Lemercier | — | 07 Luglio 2024 F | 184.686 | 0 | 0 | $0 |
| Robert W.A. Sellers | — | 11 Maggio 2024 F | 17.081 | 0 | 0 | $0 |
| Michael A Mussallem | — | 02 Maggio 2024 M | 4.486 | 0 | 0 | $0 |
| Martha H. Marsh | — | 12 Maggio 2023 A | 31.880 | 0 | 0 | $0 |
| Huimin Wang | — | 08 Luglio 2022 M | 99.381 | 0 | 0 | $0 |
| William J Link PHD | — | 08 Maggio 2020 A | 11.349 | 0 | 0 | $0 |
| Wesley W Von Schack | — | 01 Agosto 2019 S | 8.000 | 0 | 0 | $0 |
| Patrick B Verguet | — | 31 Maggio 2017 M | 129.137 | 0 | 0 | $0 |
| Randall J Nelson | — | 30 Settembre 2003 A | — | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 1 partecipazione
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Persona segnalante non divulgata | 05 Aprile 2001 | — | Deposito iniziale | Campagna per il consiglio di amministrazione | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 180 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| IHI · iShares Trust | 4,29% | 1.607.851 SH | 08 Agosto 2026 | Giornaliero |
| GDOC · Goldman Sachs ETF Trust | 2,98% | 6.939 NS | 31 Maggio 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,11% | 10.000 NS | 31 Maggio 2026 | N-PORT |
| ANEW · ProShares Trust | 2,02% | 1.801 NS | 31 Maggio 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,83% | 2.435 NS | 30 Aprile 2026 | N-PORT |
| PJBF · PGIM ETF Trust | 1,75% | 2.374 NS | 29 Maggio 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,75% | 10.488 NS | 31 Maggio 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,58% | 137.940 SH | 08 Agosto 2026 | Giornaliero |
| VOT · VANGUARD INDEX FUNDS | 1,14% | 4.411.246 SH | 08 Agosto 2026 | Giornaliero |
| ALTL · Pacer Funds Trust | 0,94% | 10.780 NS | 30 Aprile 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0,93% | 4.325 NS | 30 Aprile 2026 | N-PORT |
| SDG · iShares Trust | 0,90% | 17.447 SH | 08 Agosto 2026 | Giornaliero |
| FFND · Northern Lights Fund Trust II | 0,88% | 10.459 NS | 31 Maggio 2026 | N-PORT |
| IYH · iShares Trust | 0,83% | 341.366 SH | 08 Agosto 2026 | Giornaliero |
| BKDV · BNY Mellon ETF Trust II | 0,81% | 134.666 NS | 30 Aprile 2026 | N-PORT |
| NULV · Nushares ETF Trust | 0,79% | 197.378 NS | 30 Aprile 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0,79% | 22.410 NS | 30 Aprile 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,78% | 267.514 NS | 30 Aprile 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,77% | 1.733.147 SH | 08 Agosto 2026 | Giornaliero |
| NULC · Nushares ETF Trust | 0,75% | 5.090 NS | 30 Aprile 2026 | N-PORT |
| RXL · ProShares Trust | 0,73% | 6.052 NS | 31 Maggio 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,70% | 11.571 NS | 30 Aprile 2026 | N-PORT |
| IMCG · iShares Trust | 0,66% | 301.692 SH | 08 Agosto 2026 | Giornaliero |
| IXJ · iShares Trust | 0,65% | 302.050 SH | 08 Agosto 2026 | Giornaliero |
| TEC · Harbor ETF Trust | 0,61% | 491 NS | 30 Aprile 2026 | N-PORT |
| FWD · AB Active ETFs, Inc. | 0,56% | 187.544 NS | 31 Maggio 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,56% | 4.857 NS | 30 Aprile 2026 | N-PORT |
| BRNY · EA Series Trust | 0,54% | 35.555 NS | 30 Aprile 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,53% | 24.654 NS | 31 Maggio 2026 | N-PORT |
| SUSA · iShares Trust | 0,51% | 237.552 SH | 08 Agosto 2026 | Giornaliero |
| VO · VANGUARD INDEX FUNDS | 0,50% | 12.477.902 SH | 08 Agosto 2026 | Giornaliero |
| IWS · iShares Trust | 0,49% | 860.071 SH | 08 Agosto 2026 | Giornaliero |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,42% | 44.305 NS | 30 Aprile 2026 | N-PORT |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0,40% | 193.493 NS | 30 Aprile 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 3.768 NS | 30 Aprile 2026 | N-PORT |
| IWR · iShares Trust | 0,36% | 2.320.860 SH | 08 Agosto 2026 | Giornaliero |
| IMCB · iShares Trust | 0,34% | 63.843 SH | 08 Agosto 2026 | Giornaliero |
| JGLO · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 286.558 NS | 30 Aprile 2026 | N-PORT |
| EVUS · iShares Trust | 0,31% | 12.935 SH | 08 Agosto 2026 | Giornaliero |
| NBCR · Neuberger Berman ETF Trust | 0,30% | 30.404 NS | 31 Maggio 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,29% | 156.342 SH | 08 Agosto 2026 | Giornaliero |
| XOEF · iShares Trust | 0,28% | 720 SH | 08 Agosto 2026 | Giornaliero |
| ESUM · Strategy Shares | 0,27% | 5.033 NS | 30 Aprile 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,27% | 189.108 NS | 30 Aprile 2026 | N-PORT |
| WINN · Harbor ETF Trust | 0,24% | 31.226 NS | 30 Aprile 2026 | N-PORT |
| DEUS · DBX ETF Trust | 0,24% | 7.428 NS | 29 Maggio 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 887 NS | 30 Aprile 2026 | N-PORT |
| FFLG · FIDELITY COVINGTON TRUST | 0,22% | 15.544 NS | 30 Aprile 2026 | N-PORT |
| CAPE · DoubleLine ETF Trust | 0,22% | 7.122 NS | 31 Marzo 2026 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0,21% | 42.168 NS | 31 Maggio 2026 | N-PORT |